Dr. Irit Yaniv

Proventis is pioneering the future of male contraception with a reliable, long-term, reversible implant designed to empower men with proactive family planning. With unintended pregnancies constituting 40% of annual pregnancies worldwide, there is a growing need for male contraception methods, other than condoms and vasectomy. Our innovative set-and-forget implant will provide men with a reliable contraceptive protection without the need for daily attention or interruption. It is designed to conveniently be placed by a physician in a quick, minimally invasive, in-office procedure, and similarly deactivated upon request, to regain fertility. At Proventis, we are dedicated to advancing reproductive health through scientific excellence and strategic collaborations. We invite leading urologists, key opinion leaders, and forward-thinking investors to join us on our mission to redefine the landscape of male contraceptives. 

Developing a game changing device for the delaying of preterm birth, which is the most common pregnancy complication (1 in 10 women worldwide), and the leading cause of child morbidity and mortality until the age of 5. PregnanTech has developed LIONESS, a novel, non-surgical solution for delaying preterm birth. Inserted in a 3-5 minute out-patient procedure, the LIONESSs unique structure allows it to stay stable in place throughout the entire pregnancy, with a self-release mechanism in case of active labor. ​ LIONESS was successfully tested in a range of preclinical studies, and a first in women (FIH) clinical safety trial is currently in progress. Findings are reassuring and attest to the vast potential of the device. We are planning on conducting a multi-center pivotal trial next year, and are actively looking for medical institutions worldwide to help us conduct it. If you are a part of a medical institution and are interested in taking an active part in revolutionizing the future of obstetrics with PregnanTech, do not hesitate to reach out!

Ceretrieve Ltd. is at the forefront of addressing the ever-growing need for innovation and effectiveness in the Neurointerventional devices market. With a mission centered around improving patient outcomes and providing physicians with advanced devices, Ceretrieve focuses on enhancing interventional device maneuverability, stability, reliability, and overall performance. The company is actively developing a comprehensive range of devices, including distal access catheters, thrombectomy devices, and related accessories.

BioProtect is advancing rectal spacing through controllable, biodegradable balloon technology. Our proprietary balloon spacer is engineered to provide consistent, predictable separation from apex to base, enabling modern, high-precision radiation therapy. The FDA-cleared BioProtect Balloon Spacer has shown reduced rectal dose, a favorable safety profile, and durable preservation of bowel, urinary, and sexual quality of life through 48 months. Its performance supports use across today’s advanced prostate cancer treatment regimens, including hypofractionation and SBRT.

The growing number of connected medical devices in hospital networks has introduced a new breed of threats that healthcare organizations cannot address with IT cybersecurity solutions. Cynerio’s mission is to empower healthcare CISOs and give them full control over the security of their connected clinical engineering and IoT ecosystem, ensuring data protection, service continuity and patient safety. With Cynerio’s solution, security teams can see which medical and IoT devices are connected, understand their associated risks, and protect against harmful cyber-attacks.

Immunovative Therapies, Ltd. (Jerusalem) and our subsidiaries, Immunovative Clinical Research, Inc. (USA) and Immunovative (Thailand) Co., Ltd. (Bangkok) is the licensor and exclusive consultant to Mirror Biologics, Inc. (Tampa) and Mirror Biologics, Ltd. (Jerusalem). As exclusive consultants, we assist and provide support to Mirror to advance our immunotherapy drug candidate,AlloStim, to commercialization. We provide drug depo management, blood donor center support, clinical site management services. In addition, we are actively collaborating with Mirror to design and build automated commercial-scale cell manufacturing pods and plug-and-play disposable sets and assisting to operate a clinical research center in Tampa and Bangkok.

MetaCure, member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients. MetaCure develops, produces and sells the DIAMOND therapy, an alternative to insulin, delivered by a proprietary implantable device system. DIAMOND is intended to treat type 2 diabetes in obese patients who are refractory to oral medication. The safety and efficacy of the DIAMOND therapy has been validated in clinical trials encompassing over 300 patients, which demonstrated it is as effective as insulin treatment while avoiding most of the associated side effects and avoiding the inconvenience of frequent blood tests and injections. DIAMOND is delivered by a pacemaker-like device implanted in the abdomen to deliver gentle electrical signals to the stomach when eating, which improves glycemic control and causes weight loss. The system has received CE mark and is approved for sale in Europe, Australia and other international markets. DIAMOND is not approved for use in the USA. For more information visit www.MetaCure.com

Proventis is pioneering the future of male contraception with a reliable, long-term, reversible implant designed to empower men with proactive family planning. With unintended pregnancies constituting 40% of annual pregnancies worldwide, there is a growing need for male contraception methods, other than condoms and vasectomy. Our innovative set-and-forget implant will provide men with a reliable contraceptive protection without the need for daily attention or interruption. It is designed to conveniently be placed by a physician in a quick, minimally invasive, in-office procedure, and similarly deactivated upon request, to regain fertility. At Proventis, we are dedicated to advancing reproductive health through scientific excellence and strategic collaborations. We invite leading urologists, key opinion leaders, and forward-thinking investors to join us on our mission to redefine the landscape of male contraceptives. 

Escala Medical is a women’s health company advancing pelvic reconstructive surgery through surgeon-driven innovation. Our flagship technology, the Mendit™ Pelvic Ligament Fixation System, supports sacrospinous ligament fixation across anterior, posterior, and percutaneous vaginal approaches: Every approach, one solution. Designed to integrate seamlessly into standard vaginal workflows, Mendit offers flexible suture options and a removable, retrievable anchor design, enabling precise placement while supporting efficiency, reproducibility, and strong patient outcomes. Follow us on Instagram: @escala_medical

Developing a game changing device for the delaying of preterm birth, which is the most common pregnancy complication (1 in 10 women worldwide), and the leading cause of child morbidity and mortality until the age of 5. PregnanTech has developed LIONESS, a novel, non-surgical solution for delaying preterm birth. Inserted in a 3-5 minute out-patient procedure, the LIONESSs unique structure allows it to stay stable in place throughout the entire pregnancy, with a self-release mechanism in case of active labor. ​ LIONESS was successfully tested in a range of preclinical studies, and a first in women (FIH) clinical safety trial is currently in progress. Findings are reassuring and attest to the vast potential of the device. We are planning on conducting a multi-center pivotal trial next year, and are actively looking for medical institutions worldwide to help us conduct it. If you are a part of a medical institution and are interested in taking an active part in revolutionizing the future of obstetrics with PregnanTech, do not hesitate to reach out!

Ceretrieve Ltd. is at the forefront of addressing the ever-growing need for innovation and effectiveness in the Neurointerventional devices market. With a mission centered around improving patient outcomes and providing physicians with advanced devices, Ceretrieve focuses on enhancing interventional device maneuverability, stability, reliability, and overall performance. The company is actively developing a comprehensive range of devices, including distal access catheters, thrombectomy devices, and related accessories.

Almeda Ventures - The Next Generation of HealthTech Investments Investing in Medical Device, Digital Health and Bio-Convergence